Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU
This study is currently recruiting participants.
Verified by Emory University, March 2008
Sponsors and Collaborators: Emory University
Sanofi-Aventis
Grady Memorial Hospital, Atlanta
Piedmont Hospital, Atlanta
University of Tennessee
University of Washington
Information provided by: Emory University
ClinicalTrials.gov Identifier: NCT00394524
  Purpose

High blood sugars increase the risk of complications and death in diabetic patients admitted to the hospital. Recent studies hve shown that strict blood sugar control with intravenous (IV) insulin lowers the risk of such complications and death in the ICU. Several insulin infusion protocols have been reported in the literature, but it is not known which is the best. These protocols use tables and formulas that may be confusing and difficult to follow. To facilitate patient care, insulin protocols could be placed on a computer and used at the patient's bedside to direct the nursing staff administering the IV insulin. The Glucommander is one of such computer-derived insulin infusion protocol which has been used successfully in patients with diabetes since 1984. We hypothesize that management of inpatient hyperglycemia with a computer-guided intravenous infusion protocol will facilitate smoother glycemic control with a lower rate of low blood sugars than treatment following a standard insulin infusion algorithm in the medical intensive care unit. We will aim to determine differences in glycemic control between treatment with a computer-guided intravenous infusion protocol (Glucommander) and a standard insulin infusion algorithm in critically ill patients in the ICU.


Condition Intervention
Diabetes or With New Hyperglycemia
Device: Computer-guided IV insulin infusion (Glucommander)
Drug: IV insulin glulisine

Drug Information available for: Insulin Insulin glulisine
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Comparative Trial Between a Computer-Guided Intravenous Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU

Further study details as provided by Emory University:

Primary Outcome Measures:
  • The primary outcome of the study is to determine
  • differences in glycemic control as measured by mean daily blood
  • glucose concentration between treatment groups.

Secondary Outcome Measures:
  • Secondary outcomes include differences between treatment groups
  • in any of the following measures: number of hypoglycemic events
  • (blood glucose < 60 mg/dl), length of ICU stay and length of hospital stay,
  • and number of hyperglycemic episodes (blood glucose > 200 mg/dl).

Estimated Enrollment: 180
Study Start Date: June 2006
Estimated Study Completion Date: August 2008
Estimated Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Research Summary:

Increasing evidence from observational studies in hospitalized patients with and without diabetes indicates that hyperglycemia is a predictor of poor outcome. Blood glucose control with intensive insulin therapy in patients with acute critical illness reduces the risk of multiorgan failure and systemic infection, and decreases short- and long-term mortality.

The use of intravenous insulin infusion is the preferred route of insulin administration for the management of diabetic subjects with diabetic ketoacidosis and nonketotic hyperosmolar state, intraoperative and postoperative care, the postoperative period following heart surgery and organ transplantation, acute myocardial infarction, stroke, and critical care illness. Some of these settings may be characterized by, or associated with, severe or rapidly changing insulin requirements, generalized patient edema, impaired perfusion of subcutaneous sites, requirement for pressor support, and/or use of total parenteral nutrition. In these settings, the intravenous route for insulin administration has been considered superior than the subcutaneous injection of split-mixed regimen of intermediate and regular insulin with respect to rapidity of effect in controlling hyperglycemia, overall ability to achieve glycemic control, and most importantly, preventing hypoglycemic episodes. Recently, several insulin infusion protocols have been reported in the literature; these algorithms and formulas, however, may be confusing and difficult to follow and may increase the risk of dosing errors. To facilitate patients care, insulin algorithms could be placed on a computer and used at the patient bedside to direct the nursing staff administering the intravenous insulin. The Glucommander is one of such computer-derived insulin infusion protocol which has been used successfully in over 5,802 patients with diabetes between 1984 and 1998. We hypothesize that management of inpatient hyperglycemia with a computer-guided intravenous infusion protocol will facilitate smoother glycemic control with a lower rate of hypoglycemic events than treatment following a standard insulin infusion algorithm in critically ill patients in medical the ICU. We will aim to determine differences in glycemic control between treatment with a computer-guided intravenous infusion protocol (Glucommander) and a standard insulin infusion algorithm in critically ill patients in the ICU.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females between the ages of 18 and 70 years admitted to a medical ICU
  2. A known history of diabetes mellitus or with new hyperglycemia untreated or treated by diet, insulin therapy or with any combination of antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).

    • Blood glucose greater than 120 mg/dl on ≥ 2 occasions for known, treated diabetics or greater than 140 mg/dl on ≥ 2 occasions for those with new hyperglycemia.
  3. Subjects must have an admission blood glucose < 400 mg/dL, without laboratory evidence of diabetic ketoacidosis (serum bicarbonate < 18 mEq/L or positive serum or urinary ketones).

Exclusion Criteria:

  1. Subjects with acute hyperglycemic crises such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state [38].
  2. Patients with known HIV, severely impaired renal function (serum creatinine ≥3.0 mg/dl).
  3. Patients with mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
  4. Female subjects who are pregnant or breast feeding at time of enrollment into the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00394524

Contacts
Contact: Guillermo E Umpierrez, MD 4047781665 geumpie@emory.edu
Contact: Dawn D Smiley, MD 4047781664 dsmiley@emory.edu

Locations
United States, Georgia
Grady Memorial Hospital Recruiting
Atlanta, Georgia, United States, 30303
Principal Investigator: Guillermo E Umpierrez, MD            
Sub-Investigator: Dawn D Smiley, MD            
Piedmont Hopsital Recruiting
Atlanta, Georgia, United States, 30309
Sub-Investigator: Bruce ` Bode, MD            
United States, Tennessee
University of Tennessee Health Science Center, Memphis Not yet recruiting
Memphis, Tennessee, United States, 38103
Sub-Investigator: Abbas Kitabchi, PhD,MD            
United States, Washington
University of Washington, Seattle Not yet recruiting
Seattle, Washington, United States, 98195
Sub-Investigator: Irl B Hirsch, MD            
Sponsors and Collaborators
Emory University
Sanofi-Aventis
Grady Memorial Hospital, Atlanta
Piedmont Hospital, Atlanta
University of Tennessee
University of Washington
Investigators
Principal Investigator: Guillermo E Umpierrez, MD Emory University SOM/Grady Health System
Study Director: Bruce Bode, MD Piedmont Hospital
Study Director: Abbas E Kitabchi, PhD,MD University of Tennessee Health Science Center, Memphis
Study Director: Irl B Hirsch, MD University of Washington
  More Information

Responsible Party: Emory University School of Medicine ( Guillermo Umpierrez, MD )
Study ID Numbers: 830-2005, IRB 830-2005
Study First Received: October 31, 2006
Last Updated: March 11, 2008
ClinicalTrials.gov Identifier: NCT00394524  
Health Authority: United States: Institutional Review Board

Keywords provided by Emory University:
ICU
hyperglycemia
glucommander

Study placed in the following topic categories:
Insulin glulisine
Metabolic Diseases
Hyperglycemia
Diabetes Mellitus
Metabolic disorder
Glucose Metabolism Disorders
Insulin

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009